FMR LLC's Form 4 filing
Structure Therapeutics Inc. (GPCR) · filed Dec 10, 2025
- Accession no.
- 0001193125-25-313977
- Filed
- Dec 10, 2025
- Trade date
- Dec 8, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 10 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| FMR LLCCIK 0000315066 | 10% Owner, Other: See Remark 1 |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −2,127 | $92.52F2 | −$65,596.68 | 3,393 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −549 | $94.00F3 | −$17,202 | 3,210 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −1,425 | $94.61F4 | −$44,939.75 | 2,735 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −4,242 | $61.05F5 | −$86,324.7 | 1,321 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −3,960 | $61.45F6 | −$81,114 | 1 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −25,011 | $92.52F2 | −$771,339.24 | 39,918 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −6,477 | $94.00F3 | −$202,946 | 37,759 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −16,767 | $94.61F4 | −$528,775.29 | 32,170 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −49,905 | $61.05F5 | −$1,015,566.75 | 15,535 | Indirect | |
| Dec 8, 2025 | Ordinary Shares | SSaleDisposed | −46,605 | $61.45F6 | −$954,625.75 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $92.29 to $92.93. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Referenced by the price of 2 transactions in Table II.
- F3
The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $93.27 to $94.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Referenced by the price of 2 transactions in Table II.
- F4
The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $94.28 to $94.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Referenced by the price of 2 transactions in Table II.
- F5
The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $60.32 to $61.31. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Referenced by the price of 2 transactions in Table II.
- F6
The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $61.32 to $61.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Referenced by the price of 2 transactions in Table II.
Remarks
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.